Publication:
Malignancy Rate Associated with Bethesda Category III (AUS/FLUS) with and Without Repeat Fine Needle Aspiration Biopsy

dc.authorscopusid7003782364
dc.authorscopusid13407057000
dc.authorscopusid22934849400
dc.contributor.authorKuru, B.
dc.contributor.authorAtmaca, Ayşegül
dc.contributor.authorKefeli, M.
dc.date.accessioned2020-06-21T13:33:28Z
dc.date.available2020-06-21T13:33:28Z
dc.date.issued2016
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Kuru] Bekir, Department of General Surgery, Ondokuz Mayis Üniversitesi, Samsun, Turkey, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Atmaca] Ayşegül, Department of Internal Medicine, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Kefeli] Mehmet, Department of Pathology, Ondokuz Mayis Üniversitesi, Samsun, Turkeyen_US
dc.description.abstractBackground Selection of nodules for surgery diagnosed as Bethesda category III [atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) category] is important. It was aimed to define the malignancy rates associated with and without repeat fine needle aspiration biopsy (FNAB) and to define the contribution of repeat FNAB to triage to surgery or observation in nodules with AUS/FLUS FNAB. Methods The records of all patients with nodules who underwent FNAB and classified by Bethesda reporting system as AUS/FLUS at their institution were reviewed. Malignancy rates for patients with AUS/FLUS FNAB with and without repeat FNAB were calculated. Results Of the 582 patients who were classified as AUS/FLUS on initial FNAB, 179 underwent surgery with an associated malignancy rate of 22.9% (upper boundary). Risk of malignancy among all patients with AUS/FLUS nodules was 7% (lower boundary). The upper and lower boundaries of the malignancy rates with and without repeat FNAB were 38.6% and 15.6% for resected patients, and 13% and 4.6% for all patients, respectively. Reclassification rate with repeat FNAB was 56%. Conclusion The findings showed that repeat FNAB for initial AUS/FLUS category was associated with a significantly increased malignancy rate compared with those without repeat FNAB. Repeat FNAB could help selection of patients with AUS/FLUS to triage to surgery. Therefore, repeat FNAB for nodules with AUS/FLUS on initial FNAB was suggested. © 2016 Wiley Periodicals, Inc.en_US
dc.identifier.doi10.1002/dc.23456
dc.identifier.endpage398en_US
dc.identifier.issn8755-1039
dc.identifier.issn1097-0339
dc.identifier.issue5en_US
dc.identifier.pmid26917413
dc.identifier.scopus2-s2.0-84959432402
dc.identifier.scopusqualityQ3
dc.identifier.startpage394en_US
dc.identifier.urihttps://doi.org/10.1002/dc.23456
dc.identifier.volume44en_US
dc.identifier.wosWOS:000374343300006
dc.identifier.wosqualityQ4
dc.language.isoenen_US
dc.publisherJohn Wiley and Sons Inc. P.O.Box 18667 Newark NJ 07191-8667en_US
dc.relation.ispartofDiagnostic Cytopathologyen_US
dc.relation.journalDiagnostic Cytopathologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAtypia of Undetermined Significanceen_US
dc.subjectBethesda Category IIIen_US
dc.subjectMalignancy Rates for AUS/FLUSen_US
dc.subjectRepeat FNAB for Initial AUS/FLUS Categoryen_US
dc.titleMalignancy Rate Associated with Bethesda Category III (AUS/FLUS) with and Without Repeat Fine Needle Aspiration Biopsyen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files